<DOC>
	<DOCNO>NCT02869789</DOCNO>
	<brief_summary>A study evaluate safety Nivolumab give combination Ipilimumab patient advance cancer . The initial group enroll patient newly diagnose Stage 4 non-small cell lung cancer come back .</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study Safety Nivolumab Combination With Ipilimumab Treat Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Histologically confirm Stage 4 recurrent nonsmall cell lung cancer Eastern Cooperative Oncology Group ( ECOG ) score 01 ( Physically able carry light housework office work fully active cancer ) No prior systemic anticancer therapy ( include EGFR ALK inhibitor ) Tissue Programmed deathligand 1 ( PDL1 ) result available Untreated brain metastasis An active malignancy require concurrent intervention Active , know suspected autoimmune disease Carcinomatous meningitis , mean inflammation cover brain , cause cancer Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>